Heart:射血分数保留的心力衰竭患者限盐与不良结局风险的关系

2022-07-21 MedSci原创 MedSci原创

严格限制烹饪盐摄入与HFpEF患者预后不良相关,且在年轻和非白人患者中更为明显。临床医生在给HFpEF患者提供限制盐的建议时应谨慎。

心力衰竭(HF)的患病率在全球范围内呈上升趋势,射血分数保留的心力衰竭(HFpEF)在HF人群中所占比例逐渐升高。在HF指南中,限制盐摄入量建议范围为<1.5-<3克/天,然而,这些建议是基于饮食钠摄入可能导致体液潴留和住院风险的观察数据。对于HF患者,尤其是射血分数保留的心力衰竭(HFpEF)患者,最佳的限盐措施仍存在争议。

近日,心脏病领域权威杂志Heart上发表了一篇研究文章,该研究旨在探讨烹饪限盐与HFpEF患者临床预后风险的关系。

研究人员采用Cox比例风险模型和亚分布风险模型对来自美洲的1713名HFpEF患者进行了二次分析。烹饪盐得分是自制食品准备过程中自报的盐添加量的总和。该研究的主要终点是心血管死亡、心衰住院和心脏骤停的复合终点,次要终点是全因死亡、心血管死亡和心衰住院。

与烹饪盐评分为0的患者相比,烹饪盐评分为>0的患者主要终点风险(HR=0.760,95%CI为0.638~0.906,p=0.002)和HF住院风险(HR=0.737,95%CI为0.603~0.900,p=0.003)显著降低,但全因(HR=0.838,95%CI为0.684~1.027,p=0.088)或心血管死亡(HR=0.782,95%CI为0.598~1.020,p=0.071)风险并非如此。使用倾向评分匹配基线特征的敏感性分析和对主要在家做饭的患者进行的敏感性分析得出了类似的结果。亚组分析提示,在≤70岁的患者和非白种人中,过度严格的限盐与不良预后之间的关联更为密切。

由此可见,严格限制烹饪盐摄入与HFpEF患者预后不良相关,且在年轻和非白人患者中更为明显。临床医生在给HFpEF患者提供限制盐的建议时应谨慎。

原始出处:

Jiayong Li.et al.Salt restriction and risk of adverse outcomes in heart failure with preserved ejection fraction.heart.2022.https://heart.bmj.com/content/early/2022/06/07/heartjnl-2022-321167

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1746332, encodeId=e4611e46332a7, content=<a href='/topic/show?id=699a46801f4' target=_blank style='color:#2F92EE;'>#射血分数保留#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46801, encryptionId=699a46801f4, topicName=射血分数保留)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c84e35706999, createdName=lixiao3338, createdTime=Fri Feb 10 08:37:42 CST 2023, time=2023-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1820530, encodeId=c1cb182053033, content=<a href='/topic/show?id=c87f10089032' target=_blank style='color:#2F92EE;'>#风险的关系#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100890, encryptionId=c87f10089032, topicName=风险的关系)], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/cc81592b507031e3cfd8d4c57911d98b/62c22832a9474aea1ca90ca058aebc03.jpg, createdBy=bed5446, createdName=limedical1974, createdTime=Thu Oct 13 10:37:42 CST 2022, time=2022-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357948, encodeId=48ca135e948e4, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Jul 22 09:37:42 CST 2022, time=2022-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563635, encodeId=7dda15636350f, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Fri Jul 22 09:37:42 CST 2022, time=2022-07-22, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1746332, encodeId=e4611e46332a7, content=<a href='/topic/show?id=699a46801f4' target=_blank style='color:#2F92EE;'>#射血分数保留#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46801, encryptionId=699a46801f4, topicName=射血分数保留)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c84e35706999, createdName=lixiao3338, createdTime=Fri Feb 10 08:37:42 CST 2023, time=2023-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1820530, encodeId=c1cb182053033, content=<a href='/topic/show?id=c87f10089032' target=_blank style='color:#2F92EE;'>#风险的关系#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100890, encryptionId=c87f10089032, topicName=风险的关系)], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/cc81592b507031e3cfd8d4c57911d98b/62c22832a9474aea1ca90ca058aebc03.jpg, createdBy=bed5446, createdName=limedical1974, createdTime=Thu Oct 13 10:37:42 CST 2022, time=2022-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357948, encodeId=48ca135e948e4, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Jul 22 09:37:42 CST 2022, time=2022-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563635, encodeId=7dda15636350f, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Fri Jul 22 09:37:42 CST 2022, time=2022-07-22, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1746332, encodeId=e4611e46332a7, content=<a href='/topic/show?id=699a46801f4' target=_blank style='color:#2F92EE;'>#射血分数保留#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46801, encryptionId=699a46801f4, topicName=射血分数保留)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c84e35706999, createdName=lixiao3338, createdTime=Fri Feb 10 08:37:42 CST 2023, time=2023-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1820530, encodeId=c1cb182053033, content=<a href='/topic/show?id=c87f10089032' target=_blank style='color:#2F92EE;'>#风险的关系#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100890, encryptionId=c87f10089032, topicName=风险的关系)], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/cc81592b507031e3cfd8d4c57911d98b/62c22832a9474aea1ca90ca058aebc03.jpg, createdBy=bed5446, createdName=limedical1974, createdTime=Thu Oct 13 10:37:42 CST 2022, time=2022-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357948, encodeId=48ca135e948e4, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Jul 22 09:37:42 CST 2022, time=2022-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563635, encodeId=7dda15636350f, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Fri Jul 22 09:37:42 CST 2022, time=2022-07-22, status=1, ipAttribution=)]
    2022-07-22 zhaojie88
  4. [GetPortalCommentsPageByObjectIdResponse(id=1746332, encodeId=e4611e46332a7, content=<a href='/topic/show?id=699a46801f4' target=_blank style='color:#2F92EE;'>#射血分数保留#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46801, encryptionId=699a46801f4, topicName=射血分数保留)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c84e35706999, createdName=lixiao3338, createdTime=Fri Feb 10 08:37:42 CST 2023, time=2023-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1820530, encodeId=c1cb182053033, content=<a href='/topic/show?id=c87f10089032' target=_blank style='color:#2F92EE;'>#风险的关系#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100890, encryptionId=c87f10089032, topicName=风险的关系)], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/cc81592b507031e3cfd8d4c57911d98b/62c22832a9474aea1ca90ca058aebc03.jpg, createdBy=bed5446, createdName=limedical1974, createdTime=Thu Oct 13 10:37:42 CST 2022, time=2022-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357948, encodeId=48ca135e948e4, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Jul 22 09:37:42 CST 2022, time=2022-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563635, encodeId=7dda15636350f, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Fri Jul 22 09:37:42 CST 2022, time=2022-07-22, status=1, ipAttribution=)]
    2022-07-22 slcumt

相关资讯

Eur Heart J:饮酒、心脏生物标志物与房颤风险和不良结局的关系

与其他心血管疾病(例如HF)相比,即使每天少量饮酒1.2杯/天也能增加房颤的患病风险,因此不能通过心脏生物标志物浓度或HF来解释饮酒与房颤之间的相关性。

Lancet Respir Med:近期哮喘发作患者感染COVID-19后发生不良结局的风险加大

近期哮喘发作患者应该是COVID-19增强疫苗的优先群体。

Stroke:非高密度脂蛋白胆固醇可预测急性缺血性卒中患者的不良结局

non-HDL-C水平可能是急性缺血性卒中患者1年内复发和全因死亡的预测因子。

Acta Psychiatrica Scandinavica:精神疾病的严重程度和COVID - 19不良结局有关

对COVID - 19患者而言,有精神分裂症谱系障碍、双相情感障碍或单相抑郁病史或有需要积极治疗的精神障碍病史可能是不利结局的重要危险因素。

JAHA:经导管主动脉瓣置换后合并症的负担和不良结局

TAVR治疗的高危患者临床结局较差。标准风险评估未能充分反映与合并症负担相关的风险,对合并症进行系统的评估可能会改善TAVR患者的风险分层。

JAHA:低循环肌素水平与经导管主动脉瓣植入术患者不良结局相关

循环肌素是TAVI患者1年总生存率的独立预测因子。与EuroSCOREII相结合,循环肌素可能有助于提高对低至中等临床风险接受TAVI的患者死亡的预测水平。